The therapeutic efficacy of IL-17 inhibitors in psoriatic arthritis, regardless of prior TNF inhibitor exposure, may contribute to the comparability between the drug retention of IL-17 inhibitors used for psoriasis aggravation and that of TNF inhibitors. The gene discussed is TNF; the disease is psoriatic arthritis.